JENSCARE-B (09877) expects its mid-term revenue to increase by 385% to 400% year-on-year.

JENSCARE-B (09877) announced that the group expects to achieve revenue of approximately RMB 63 million to 65 million for the six months ending June 30, 2026, representing a year-on-year increase of 385% to 400%. Other income and gains are estimated at approximately RMB 9 million to 11 million, totaling around RMB 72 million to 76 million, which will increase by RMB 47 million to 51 million compared to the same period last year, representing a year-on-year increase of 188% to 204%. The main reasons for performance growth during the reporting period include: 1. The commercialization of the group's catheter-based artificial aortic valve system, Ken-Valve, continues to achieve steady revenue growth. Ken-Valve is suitable for aortic regurgitation or combined stenosis, and its product design features and operational advantages have facilitated rapid adoption of the procedure across various levels of medical institutions; 2. The group is actively conducting fee-based clinical implantations of multiple interventional products for structural heart disease overseas. The excellent clinical outcomes and application advantages of these products have received high praise from global key opinion leaders and experts, meeting the substantial long-standing unmet clinical needs for structural heart disease worldwide. In addition, the group will continue to promote the development of multiple innovative product pipelines and deepen its international business layout to achieve rapid revenue growth; it will also enhance management efficiency and reduce operational costs in production, supply chain, and operational management to realize its long-term strategic goals.